Administration of cyclosporine in immune-mediated dermatoses

( views:182, downloads:0 )
GAO Min(Department of Dermatology and Venereology, First Affiliated Hospital and Institute of Dermatology, Anhui Medical University, Hefei 230022, China)
Journal Title:
International Journal of Dermatology and Venereology
Volume 37, Issue 05, 2011
Key Word:
Skin diseases;Immunity;Cyclosporine

Abstract: As a calcineurin inhibitor, cyclosporine selectively acts on T lymphocytes. It has been approved to be used in the treatment of psoriasis by the U.S. Food and Drug Administration since 1997. Also, it could be applied to treat some other immune-mediated dermatoses, such as psoriatic arthritis, atopic dermatitis, pyoderma gangrenosum, blistering disorders, lichen planus, chronic idiopathic urticaria and connective tissue diseases. In the last decade, many dermatologists have hesitated to use it in their clinical practice because of its toxicity profile. However, cyclosporine has been proved to be safe and effective for the treatment of some immune-mediated dermatoses. The author summarizes the outcomes of and considerations in the treatment of immune-mediated dermatoses with cyclosporine, in hope to make dermatologists feel comfortable and safe incorporating cyclosporine into their prescribing regimens.

  • [1]Amor KT,Ryan C,Menter A.The use of cyclosporine in dermatology:part Ⅰ.J Am Acad Dermatol,2010,63(6):925-948.
  • [2]Lee EJ,Shin MK,Kim NI.A clinical trial of combination therapy with eltanercept and low dose cyclosporine for the treatment of refractory psoriasis.Ann Dermatol,2010,22(2):138-142.
  • [3]Menter A,Korman NJ,Elmets CA,et al.Guidelines of care for the management of psoriasis and psoriatic arthritis:section 4.Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.J Am Acad Dermatol,2009,61(3):451-485.
  • [4]Ho VC,Griffiths CE,Albrecht G,et al.Intermittent short courses of cyclosporin (Neoral (R)) for psoriasis unresponsive to topical therapy:a 1-year multicentre,randomized study.The PISCES Study Group.Br J Dermatol,1999,141 (2):283-291.
  • [5]Ho VC,Griffiths CE,Berth-Jones J,et al.Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis:a 2-year cohort study.J Am Acad Dermatol,2001,44(4):643-651.
  • [6]García-Bustínduy M,Escoda M,Guimerá FJ,et al.Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis:a retrospective case series.J Eur Acad Dermatol Venereol,2004,18(2):169-172.
  • [7]R osenbach M, Hsu S, Korman NJ,et al. Treatment of erythrodermic psoriasis:from the medical board of the National Psoriasis Foundation.J Am Acad Dermatol,2010,62(4):655-662.
  • [8]Davison SC,Morris-Jones R,Powles AV,et al.Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis.Br J Dermatol,2000,143(2):405-407.
  • [9]Salvarani C,Macchioni P,Olivieri I,et al.A comparison of cyclosporine, sulfasalazine,and symptomatic therapy in the treatment of psoriatic arthritis.J Rheumatol,2001,28 (10):2274-2282.
  • [10]Sarzi-Puttini P,Cazzola M,Panni B,et al.Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis.Rheumatol Int,2002,21 (6):234-238.
  • [11]Haw S,Shin MK,Haw CR.The efficacy and safety of long-term oral cyclosporine treatment for patients with atopic dermatitis.Ann Dermatol,2010,22(1):9-15.
  • [12]Czech W,Br(a)utigam M,Weidinger G,et al.A body-weightindependent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life.J Am Acad Dermatol,2000,42(4):653-659.
  • [13]Griffiths CE,Katsambas A,Dijkmans BA,et al.Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol,2006,155(Suppl 2):1-16.
  • [14]Turner RB,Emer JJ,Weill M,et al.Rapid resolution of pyoderma gangrenosum after treatment with intravenous cyclosporine.J Am Acad Dermatol,2010,63 (3):e72-74.
  • [15]Fujii K,Kanno Y,Konishi K,et al.Short-term elretinate therapy for prurigo chronica multiformis.J Dermatol,2002,29(3):146-151.
  • [16]McAleer MA,Powell FC,Devaney D,et al.Infantile pyoderma gangrenosum.J Am Acad Dermatol,2008,58(2 Suppl):S23-28.
  • [17]Erkko P,Granlund H,Remitz A,et al.Double-blind placebocontrolled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis.Br J Dermatol,1998,139(6):997-1004.
  • [18]Lapidoth M,David M,Ben-Amitai D,et al.The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus:preliminary study.J Am Acad Dermatol,1994,30(5 Pt 1):752-757.
  • [19]Mirmirani P,Willey A, Price VH.Short course of oral cyclosporine in lichen planopilaris.J Am Acad Dermatol,2003,49(4):667-671.
  • [20]Kessel A,Toubi E.Extended cyclosporine-A--treatment forsevere chronic urticaria.Harefuah,2006,145(6):411-414.
  • [21]Giuliodori K,Ganzetti G,Campanati A,et al.A non-responsive chronic autoimmune urticaria in a 12-year-old autistic girl treated with cyclosporin.J Eur Acad Dermatol Venereol,2009,23(5):619-620.
  • [22]Engineer L,Ahmed AR.Emerging treatment for epidermolysis bullosa acquisita.J Am Acad Dermatol,2001,44(5):818-828.
  • [23]Kotani T,Makino S,Takeuchi T,et al.Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/ subacute interstitial pneumonia in dermatomyositis.J Rheumatol,2008,35(2):254-259.
  • [24]Siepmann D,Luger TA,St(a)nder S.Antipruritic effect of cyclosporine microemulsion in prurigo nodularis:results of a case series.J Dtsch Dermatol Ges,2008,6(11):941-946.
  • [25]Young EW,Ellis CN,Messana JM,et al.A prospective study of renal structure and function in psoriasis patients treated with cyclosporin.Kidney Int,1994,46(4):1216-1222.
  • [26]Lowe NJ,Wieder JM,Rosenbach A,et al.Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure.J Am Acad Dermatol,1996,35 (5 Pt1):710-719.
  • [27]Faerber L,Braeutigam M,Weidinger G,et al.Cyclosporine in severe psoriasis.Results of a meta-analysis in 579 patients.Am J Clin Dermatol,2001,2(1):41-47.
  • [28]Paul CF,Ho VC,McGeown C,et al.Risk of malignancies in psoriasis patients treated with cyclosporine:a 5 y cohort study.J Invest Dermatol,2003,120(2):211-216.
  • [29]Somech R,Doyle J.Pseudotumor cerebri after allogeneic bone marrow transplant associated with cyclosporine a use for graftversus-host disease prophylaxis.J Pediatr Hematol Oncol,2007,29(1):66-68.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615